Relapsing-remitting multiple sclerosis (RRMS) accounts for approximately 85% of multiple sclerosis (MS) cases. It is characterized by recurrent episodes of various neurologic deficits that resolve over a short period with variable to no obvious residual deficit. Several pharmaceutical agents for MS have been approved by the U.S. Food and Drug Administration (FDA) to treat patients with clinically definite RRMS. Though none of these disease-modifying therapies (DMTs) cure the disease, all have shown efficacy in reducing clinical relapses and suppressing development of new lesions on MRI. Some slow the rate of disability progression.
How familiar are you with the management of RRMS? Test your knowledge with this quick quiz.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Christopher Luzzio, Kerstin Hellwig. Fast Five Quiz: Relapsing-Remitting Multiple Sclerosis Management - Medscape - Jun 30, 2022.
Comments